List of publications by EMBRN members
Login in for more content
You can get access to this area and its contents if you are a member of EMBRN. A membership with EMBRN provides you with access to EMBRN experimental protocols, recent papers from the EMBRN lab and an updated member list.
To become a member with EMBRN, please fill out the membership form.
A rational roadmap for SARS-CoV-2/COVID-19pharmacotherapeutic research and development: IUPHARReview 29
Summary In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening
Mast Cell Cytonemes as a Defense Mechanism against Coxiella burnetii
Summary Mast cells (MCs) are critical mediators of inflammation; however, their microbicidal activity against invading pathogens remains largely unknown. Here, we describe a nonpreviously reported antibacterial mechanism used by MCs against Coxiella burnetii, the agent of Q fever. We show that C. burnetii interaction with MCs does not result in
Progenitor mast cells and tryptase in Q fever
Summary Q fever is an infectious disease due to Coxiella burnetii. Following a primary-infection, C. burnetii may persist in some patients, leading to endocarditis and vascular infections. Mast cells (MCs), known for their role in allergic diseases, innate immunity and cardiac function, are produced by bone marrow, circulate as progenitors
Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells
Summary Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells Citation Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells. Shamri R, Dubois G, Erpenbeck VJ, Mankuta D, Sandham DA, Levi-Schaffer F. Clin Exp Allergy. 2019 Feb;49(2):255-257. doi: 10.1111/cea.13304. Epub 2018 Nov 25. PMID: 30379368 Download